NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Alzheimer's Tau Platform: Regimen A - AADvac1

Enrolling By InvitationPhase 2

Sponsor: Paul S. Aisen

Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease

Interventions: AADvac1, Donanemab

Countries: United States

The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.

Eligibility overview

Sex: ALL

Age: 50 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).

Exclusion Criteria:

* No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).

Locations (1)

San Francisco, California, United States